A new radio-enhancer, PEP503 (NBTXR3), in combination with concurrent chemoradiation in locally advanced or unresectable rectal cancer: The dose-finding part of a phase I/II trial

Pour en savoir plus sur nos technologies, nos collaborations, nos essais cliniques et d’autres sujets, contactez-nous.